Researchers identify unique bleeding syndrome linked to cirrhosis and portal hypertension

NewsGuard 100/100 Score

A unique bleeding syndrome associated with cirrhosis and portal hypertension has been identified by researchers at the Medical University of South Carolina (MUSC), Wake Forest University Medical Center, and the University of Texas Southwestern Medical Center in an article published online on April 21, 2017 by the Journal of Investigative Medicine. The syndrome is characterized by typical presentation with acute bleeding (hematemesis, melena, or hematochezia) and also the presence of chronic gastrointestinal (GI) bleeding, documented as iron deficiency anemia. The investigators have coined a term for the syndrome: acute on chronic bleeding.

"This is recognition of a common syndrome of which practicing physicians should be aware," says Principal Investigator Don C. Rockey, M.D., first author on the article, who serves as the chair of the Department of Medicine and professor of gastroenterology at MUSC.

Of the 1,460 patients with GI bleeding involved in the study, 430 (29 percent) were found to have acute on chronic GI bleeding. The bleeding in patients with upper GI bleeding was most often a result of portal hypertensive upper GI tract pathology.

The investigators advise that clinicians confronted with patients who have acute on chronic bleeding should be aware of the association of this presentation with cirrhosis and portal hypertension for appropriate diagnosis and treatment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Does IBD affect cancer risk?